SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June... Read More

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of June Initial Phase 2 data for rosnilimab in ulcerative colitis (UC) on track for Q4 2025 Ongoing Phase 1a trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator Authorized a $75... Read More

SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics , a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. “It is a pleasure to welcome John to our Board,” said Fredrik Wiklund, Chief Executive Officer of... Read More

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding common stock, par value $0.001 per share. Anaptys has cash, cash equivalents and... Read More

SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45 th Annual Healthcare... Read More

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and translational data for rosnilimab in RA in Q2 2025 Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025 Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a... Read More

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDA Demonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14... Read More

SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12,... Read More

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT. A live webcast of the presentation will be available on... Read More

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU Anaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supply Anaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE... Read More

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET. A live webcast of the presentation will be... Read More

ANB032 was well tolerated across all doses with no safety signals observed AD trial and all further investment in ANB032 will be discontinued Anticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 for rosnilimab, a PD-1+ T cell depleter and agonist Funded beyond additional clinical data catalysts including Phase 2 data in ulcerative colitis for rosnilimab and Phase 1b data for ANB033 and ANB101 Year-end... Read More

Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024 Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis (RA) in February 2025 Phase 1 trial initiated in healthy volunteers for ANB033, our anti-CD122 antagonist Reiterating cash runway through year-end 2026 SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:... Read More

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences: Guggenheim's Inaugural Healthcare Innovation... Read More

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences: 2024 Wells Fargo Healthcare Conference ,... Read More

SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on Aug. 13, 2024. The gross proceeds from this offering... Read More

Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist Top-line data accelerated and now anticipated in Q1 2025 for Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist Top-line data now anticipated in Q1 2026 for Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab IND accepted by FDA... Read More

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist; reiterating top-line data anticipated by mid 2025 and H1 2026, respectively IND submissions... Read More

All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least 24 weeks maintained clear to almost clear skin and none experienced a flare Of the remaining eight responding patients from GEMINI-1 re-randomized to placebo in GEMINI-2, 25% maintained clear to almost clear... Read More

Anaptys to receive $50 million upfront cash payment from Sagard Healthcare Prior agreement amended to now expire once Sagard receives a capped payoff of either $600 million if received by March 31, 2031 or $675 million if received thereafter SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today... Read More

BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through... Read More

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist, with top-line data anticipated by mid 2025 and H1 2026, respectively IND filings for ANB033... Read More

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen’s 44 th Annual Health Care Conference. Additionally, the company announced an upcoming presentation at the 2024 American Academy... Read More

SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim’s 6 th Annual Biotechnology Conference. Investor Conference Details Event - Guggenheim’s 6th Annual Biotechnology Conference Format – Fireside chat Date... Read More

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2024 Reiterating year-end 2023 cash and investments of $400 to $410 million and cash runway through year-end 2026 SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:... Read More

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that, for the second year in a row, it has been named a BioSpace 2024 Best Place to Work in the small employer category. “This award acknowledges the commitment we’ve made to ensuring Anaptys provides our employees with an exceptional... Read More

Initiated a global Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist Initiating in Q4 2023 a global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab Announced positive top-line Phase 3 clinical trial results of imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) Reiterating cash runway through year-end 2026 and updating expected year-end 2023 cash and investments of... Read More

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences in November: Investor Conference Details... Read More

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32 nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data... Read More

Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25. Independent medical experts and... Read More

53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo (p=0.0131) Demonstrated favorable safety and tolerability with no SAEs, low incidence and no increase of infections vs. placebo and no cases of DRESS or Guillain-Barre in imsidolimab-treated patients Only one of 30 (3.3%) imsidolimab-treated... Read More

After more than 15 years serving on AnaptysBio’s Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of... Read More

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month. Investor Conference Details: Event –... Read More

Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023 Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2 trial, in an indication yet to be announced, by year-end 2023 Daniel Faga appointed to the permanent position of president and... Read More

JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy U.S. Food and Drug Administration approval represents a potential significant driver of JEMPERLI royalties Anticipate top-line data from two GSK Phase 3 studies that include JEMPERLI to read out in 2024: the FIRST study in first-line ovarian cancer (H1 2024) and the COSTAR study in... Read More

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its senior management team are scheduled to participate in both of the upcoming investor conferences below: Event: Jefferies Healthcare... Read More

Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonist Hosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023 Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 data Initiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be... Read More

Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4 Flare control sustained on monthly subcutaneous doses through Week 16 Imsidolimab was generally safe and well tolerated with low overall ADA incidence Top-line GEMINI-1 Phase 3 trial data expected in Q4 2023 SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage... Read More

SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the company’s Board of Directors, effective immediately. Additionally, Laura J. Hamill has decided to resign from the company’s Board of Directors. “Rita is a recognized leader in rheumatology with... Read More

Results published in The New England Journal of Medicine and presented simultaneously at ESMO Virtual Plenary and SGO Annual Meeting 72% and 36% reduction in the risk of disease progression or death observed in the dMMR/MSI-H population and overall patient population, respectively Clinically meaningful overall survival trend observed at interim analysis GSK is planning regulatory submissions for the first half of 2023 SAN... Read More

Initiating a global Phase 2b trial for rosnilimab (PD-1 agonist) to treat rheumatoid arthritis anticipated Q3 2023 Initiating a global Phase 2b trial for ANB032 (BTLA agonist) to treat atopic dermatitis anticipated Q2 2023 Initiating second Phase 2 trial for rosnilimab in an indication to be announced anticipated year-end 2023 Filing IND for ANB033 (anti-CD122 antagonist) anticipated H1 2024 Top-line data from the GEMINI-1... Read More

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics today announced that Dan Faga, interim president and chief executive officer, will present at the Cowen and Company 43rd Annual Health Care Conference on Monday, March 6, 2023, at 2:50 p.m. ET / 11:50 a.m. PT. A live audio webcast of the presentation... Read More

SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share. With cash, cash equivalents and... Read More

Advancing rosnilimab, its PD-1 agonist, into a global Phase 2b trial to treat rheumatoid arthritis with study initiation in Q3 2023 Advancing ANB032, its BTLA agonist, into a global Phase 2b trial to treat atopic dermatitis with study initiation in Q2 2023 Advancing rosnilimab into a second Phase 2 trial, in an indication to be announced, with study initiation anticipated by year-end 2023 Blinded interim review of alopecia... Read More

Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer First-in-class pivotal data in endometrial cancer, if approved, to be a potential significant driver of JEMPERLI royalties to AnaptysBio SAN DIEGO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage... Read More